Clinical Trial Detail

NCT ID NCT03237377
Title Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult senior

No variant requirements are available.